期刊文献+

生命早期脂肪高峰与脂肪重积聚的流行病学研究进展

Epidemiological research progress of adiposity peak and adiposity rebound in early life
原文传递
导出
摘要 脂肪高峰(adiposity peak, AP)与脂肪重积聚(adiposity rebound, AR)是生命早期身体质量指数(body mass index, BMI)生长轨迹的最高点和最低点,也是其最明显的特征。流行病学研究报道了世界各地不同人群AP和AR出现时间和出现时的BMI值。另有研究观察了产前、产后、喂养、经济社会等因素对其出现时间和出现时BMI值的影响。更有时间跨度较大的纵向研究追踪了对其出现时间和出现时BMI值对生命后期许多负性健康结局的影响。该综述基于大量文献,总结了AP和AR的出现时间与出现时的BMI值在全球范围内的流行病学特征,生命前期与生命早期决定因素,及其可能长生的长期健康效应,为肥胖及相关慢性疾病的预防与干预工作提供科学依据,并总结了针对该研究问题目前尚存在的争议,为今后研究指明方向。 The adiposity peak(AP) and adiposity rebound(AR) are the highest and lowest points of the body mass index(BMI) growth trajectory in early life. They are also the most significant characteristics. Epidemiological studies have reported the timings and BMI magnitudes of AP and AR in different populations worldwide. Others have observed the impacts of prenatal, postpartum, feeding, economic and social factors on the timing and magnitude of them. In addition, longitudinal studies have tracked the health effect of the timing and magnitude of them on many adverse health outcomes in later life. Based on literature reviews, we summarize the global epidemiological characteristics of AP and AR, while identifying pre-and early-life determinants as well as their possible long-term health effects, so as to provide scientific evidence for the prevention and management of obesity and related chronic diseases. We also highlight current controversies regarding this issue, while outlining directions for future research.
作者 林丹 史慧静 LIN Dan;SHI Huijing(Department of Maternal,Child and Adolescent Health,School of Public Health,Fudan University,Shanghai(200032),China)
出处 《中国学校卫生》 CAS 北大核心 2022年第6期946-951,共6页 Chinese Journal of School Health
基金 上海市加强公共卫生体系建设第五轮重点学科建设项目(GWV-10.1-XK08)。
关键词 生命周期各时期 脂肪组织 流行病学研究 人体质量指数 Life cycle stages Adipose tissue Epidemiologic studies Body mass index
  • 相关文献

参考文献2

二级参考文献19

  • 1Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. IntJ Med Sci 2006;3:41-6.
  • 2Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007;132:1979-98.
  • 3Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-15.
  • 4Manns ME McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treamaent of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
  • 5Fried MW, Shiffinan ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
  • 6Arase Y, Suzuki Y, Suzuki F, et al. Efficacy of reduction therapy of natural human -interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load. Hepatol Res 2012;42:750-6.
  • 7Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources.J Gen Virol 1992;73:673-9.
  • 8Kato T, Date T, Miyamoto M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 2003;125:1808-17.
  • 9ZhongJ, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102:9294-9.
  • 10Sarasin-Filipowicz M. Interferon therapy of hepatitis C: molecular insights into success and failure. Swiss Med Wkly 2010;140:3-11.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部